Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...

Researchers have found that CAR T-cell therapy can help aging intestines heal by targeting senescent cells. In mice, it boosted regeneration, reduced inflammation, and improved nutrient absorption, ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...